Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS)
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Sample and Data Collection
2.2. Characteristics of the Adapted Questionnaires: MARS and CACHE
2.3. Cross-Cultural Adaptation
2.4. Statistical Analyses
3. Results
3.1. Characteristics of Patients Involved in the Adaptation Process
3.2. MARS
3.2.1. Questionnaire Performance
3.2.2. Questionnaire Adequacy
3.2.3. Reliability
3.2.4. Influence of Patient Demographics on Drug Adherence
3.2.5. Adherence of Hungarian Patients with IBD
3.3. CACHE
3.3.1. Questionnaire Performance
3.3.2. Questionnaire Adequacy
3.3.3. Reliability
3.3.4. The Effect of Patient Demographics on Satisfaction with the Quality of Care
3.3.5. Satisfaction with the Quality of Care among Hungarian Patients with IBD
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
CACHE | Patient satisfaction with health care in inflammatory bowel disease questionnaire |
CD | Crohn’s disease |
CFI | comparative fit index |
IBD | inflammatory bowel disease |
MARS | Medication adherence report scale |
MDT | multi-disciplinary team |
RMSEA | root mean square error of approximation |
TLI | Tucker-Lewis index |
UC | ulcerative colitis |
References
- Sýkora, J.; Pomahačová, R.; Kreslová, M.; Cvalínová, D.; Štych, P.; Schwarz, J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J. Gastroenterol. 2018, 24, 2741–2763. [Google Scholar] [CrossRef] [PubMed]
- Müller, K.E.; Lakatos, P.L.; Arató, A.; Kovács, J.B.; Várkonyi, Á.; Szűcs, D.; Szakos, E.; Sólyom, E.; Kovács, M.; Polgár, M.; et al. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2013, 57, 576–582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Freeman, K.; Ryan, R.; Parsons, N.; Taylor-Phillips, S.; Willis, B.H.; Clarke, A. The incidence and prevalence of inflammatory bowel disease in UK primary care: A retrospective cohort study of the IQVIA Medical Research Database. BMC Gastroenterol. 2021, 21, 139. [Google Scholar] [CrossRef] [PubMed]
- Lakatos, L.; Kiss, L.S.; David, G.; Pandur, T.; Erdelyi, Z.; Mester, G.; Balogh, M.; Szipocs, I.; Molnar, C.; Komaromi, E.; et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. Inflamm. Bowel Dis. 2011, 17, 2558–2565. [Google Scholar] [CrossRef]
- Taft, T.H.; Keefer, L. A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease. Clin. Exp. Gastroenterol. 2016, 9, 49–58. [Google Scholar]
- Mehta, F. Report: Economic implications of inflammatory bowel disease and its management. Am. J. Manag. Care 2016, 22, s51–s60. [Google Scholar]
- Alexoff, A.; Roginsky, G.; Zhou, Y.; Kalenda, M.; Minuskin, K.; Ehrenpreis, E.D. Inpatient Costs for Patients with Inflammatory Bowel Disease and Acute Pancreatitis. Inflamm. Bowel Dis. 2016, 22, 1095–1100. [Google Scholar] [CrossRef] [Green Version]
- Goodhand, J.; Hedin, C.R.; Croft, N.M.; Lindsay, J.O. Adolescents with IBD: The importance of structured transition care. J. Crohns Colitis 2011, 5, 509–519. [Google Scholar] [CrossRef] [Green Version]
- Morar, P.; Read, J.; Arora, S.; Hart, A.; Warusavitarne, J.; Green, J.; Sevdalis, N.; Edwards, C.; Faiz, O. Defining the optimal design of the inflammatory bowel disease multidisciplinary team: Results from a multicentre qualitative expert-based study. Frontline Gastroenterol. 2015, 4, 290–297. [Google Scholar] [CrossRef] [Green Version]
- Goodhand, J.; Dawson, R.; Hefferon, M.; Tshuma, N.; Swanson, G.; Wahed, M.; Croft, N.M.; Lindsay, J.O. Inflammatory bowel disease in young people: The case for transitional clinics. Inflamm. Bowel Dis. 2010, 16, 947–952. [Google Scholar] [CrossRef]
- Otto, C.; Tárnok, A.; Erős, A.; Szakács, Z.; Vincze, Á.; Farkas, N.; Sarlós, P. Planned Transition of Adolescent Patients with Inflammatory Bowel Disease Results in Higher Remission Rates. J. Pediatr. Nurs. 2019, 45, 62–66. [Google Scholar] [CrossRef] [Green Version]
- Cooley, W.C.; Sagerman, P.J. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 2011, 128, 182–200. [Google Scholar] [CrossRef] [Green Version]
- Callahan, S.T.; Winitzer, R.F.; Keenan, P. Transition from pediatric to adult-oriented health care: A challenge for patients with chronic disease. Curr. Opin. Pediatr. 2001, 13, 310–316. [Google Scholar] [CrossRef]
- Lakatos, P.L. Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it? World J. Gastroenterol. 2009, 15, 4234–4239. [Google Scholar] [CrossRef] [Green Version]
- van Rheenen, P.F.; Aloi, M.; Biron, I.A.; Carlsen, K.; Cooney, R.; Cucchiara, S.; Cullen, G.; Escher, J.C.; Kierkus, J.; Lindsay, J.O.; et al. European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease. J. Crohns Colitis 2017, 11, 1032–1038. [Google Scholar] [CrossRef]
- Brooks, A.J.; Smith, P.J.; Cohen, R.; Collins, P.; Douds, A.; Forbes, V.; Gaya, D.R.; Johnston, B.T.; McKiernan, P.J.; Murray, C.D.; et al. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut 2017, 66, 988–1000. [Google Scholar] [CrossRef] [Green Version]
- Erős, A.; Dohos, D.; Veres, G.; Tárnok, A.; Vincze, Á.; Tészás, A.; Zádori, N.; Gede, N.; Hegyi, P.; Sarlós, P. Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: A protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD). BMJ Open 2020, 10, e038410. [Google Scholar] [CrossRef]
- Suris, J.C.; Akre, C. Key elements for, and indicators of, a successful transition: An international Delphi study. J. Adolesc. Health 2015, 56, 612–618. [Google Scholar] [CrossRef]
- Fair, C.; Cuttance, J.; Sharma, N.; Maslow, G.; Wiener, L.; Betz, C.; Porter, J.; McLaughlin, S.; Gilleland-Marchak, J.; Renwick, A.; et al. International and Interdisciplinary Identification of Health Care Transition Outcomes. JAMA Pediatr. 2016, 170, 205–211. [Google Scholar] [CrossRef]
- van den Brink, G.; van Gaalen, M.A.C.; de Ridder, L.; van der Woude, C.J.; Escher, J.C. Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study. J. Crohns Colitis 2019, 13, 1163–1172. [Google Scholar] [CrossRef]
- Horne, R.; Weinman, J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999, 47, 555–567. [Google Scholar] [CrossRef]
- Mahler, C.; Hermann, K.; Horne, R.; Ludt, S.; Haefeli, W.E.; Szecsenyi, J.; Jank, S. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J. Eval. Clin. Pract. 2010, 16, 574–579. [Google Scholar] [CrossRef]
- Bäck, A.; Sundell, A.K.; Horne, R.; Landén, M.; Mårdby, A.C. The Medication Adherence Report Scale (MARS-5) in a Swedish sample with bipolar disorder—A pilot study. Int. J. Person Centered Med. 2012, 2, 263–270. [Google Scholar]
- Vanelli, I.; Chendo, I.; Gois, C.; Santos, J.; Levy, P. Medication adherence rating scale. Acta Med. Port. 2011, 24, 17–20. [Google Scholar] [CrossRef]
- SOLE Study Group. Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn’s Disease. Dig. Liver Dis. 2019, 51, 640–647. [Google Scholar] [CrossRef] [Green Version]
- Casellas, F.; Ginard, D.; Vera, I.; Torrejón, A. Development and testing of a new instrument to measure patient satisfaction with health care in inflammatory bowel disease: The CACHE questionnaire. Inflamm. Bowel Dis. 2013, 19, 559–568. [Google Scholar] [CrossRef]
- Weizman, A.V.; Bressler, B.; Seow, C.H.; Afif, W.; Afzal, N.M.; Targownik, L.; Nguyen, D.M.; Jones, J.L.; Huang, V.; Murthy, S.K.; et al. Providing Hospitalized Ulcerative Colitis Patients with Practice Guidelines Improves Patient-Reported Outcomes. J. Can. Assoc. Gastroenterol. 2021, 4, 131–136. [Google Scholar] [CrossRef]
- Guarini, A.; Biagini, S.; Capaldi, A.; Carretto, D.; Angelis, A.; Iudice, S.; Martino, G.; Marziali, B.; Mattiola, R.; Ongarelli, C.; et al. Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: A multicenter study. Ann. Gastroenterol. 2017, 30, 96–100. [Google Scholar] [CrossRef]
- Casellas, F.; Vera, I.; Ginard, D.; Torrejón, A. Inflammatory bowel disease patient’s satisfaction with healthcare services received. Physicians’ and nurses’ perceptions. Rev. Esp. Enferm. Dig. 2013, 105, 385–391. [Google Scholar] [CrossRef] [Green Version]
- Beaton, D.E.; Bombardier, C.; Guillemin, F.; Ferraz, M.B. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000, 25, 3186–3191. [Google Scholar] [CrossRef] [Green Version]
- Chen, P.Y.; Yang, C.M.; Morin, C.M. Validating the cross-cultural factor structure and invariance property of the Insomnia Severity Index: Evidence based on ordinal EFA and CFA. Sleep Med. 2015, 16, 598–603. [Google Scholar] [CrossRef] [PubMed]
- Hu, L.T.; Bentler, P.M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct. Equ. Modeling Multidiscip. J. 1999, 6, 1–55. [Google Scholar] [CrossRef]
- R Core Team. A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2021; Available online: https://www.R-project.org/ (accessed on 10 October 2021).
- Rosseel, Y. lavaan: An R Package for Structural Equation Modeling. J. Stat. Softw. 2012, 48, 1–36. [Google Scholar] [CrossRef] [Green Version]
- Cook, C.L.; Wade, W.E.; Martin, B.C.; Perri, M., 3rd. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J. Am. Pharm. Assoc. 2003, 45, 151–159. [Google Scholar] [CrossRef] [PubMed]
- Haynes, R.B.; Taylor, D.W.; Sackett, D.L.; Gibson, E.S.; Bernholz, C.D.; Mukherjee, J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980, 2, 757–764. [Google Scholar] [CrossRef] [Green Version]
- Inotai, A.; Csanádi, M.; Harsányi, A.; Németh, B. Drug Policy in Hungary. Value Health Reg. Issues 2017, 13, 16–22. [Google Scholar] [CrossRef]
- Panés, J.; O’Connor, M.; Peyrin-Biroulet, L.; Irving, P.; Petersson, J.; Colombel, J.-F. Improving quality of care in inflammatory bowel disease: What changes can be made today? J. Crohns Colitis 2014, 89, 919–926. [Google Scholar] [CrossRef] [Green Version]
- Ferman, M.; Lim, A.H.; Hossain, M.; Siow, G.W.; Andrews, J.M. Multidisciplinary team meetings appear to be effective in inflammatory bowel disease management: An audit of process and outcomes. Intern. Med. J. 2018, 48, 1102–1108. [Google Scholar] [CrossRef]
Characteristics | Adolescent Population (n = 122) | Adult Population (n = 164) | Overall (n = 286) |
---|---|---|---|
male/female | 58/64 | 45/119 | 103/183 |
ethnicity: Hungarian/other | 115/6 | 156/8 | 271/14 |
age (mean ± SD; yrs) | 17 ± 1 | 38 ± 11 | 29 ± 13 |
disease duration time (mean ± SD; yrs) | 10 ± 8 | 4 ± 3 | 7 ± 7 |
Crohn’s disease/ ulcerative colitis | 80/42 | 100/64 | 180/106 |
previous intestinal surgery (%) | 17 | 35 | 27 |
comorbidities (%) | 15 | 34 | 26 |
therapy (%): biologicals | 44 | 39 | 41 |
steroids | 25 | 18 | 21 |
azathioprine | 37 | 39 | 38 |
5-ASA | 59 | 56 | 55 |
Questions | Always | Often | Occasionally | Rarely | Never |
---|---|---|---|---|---|
I forget to take the medicine. | 1 (1%) | 6 (5%) | 21 (18%) | 44 (38%) | 45 (38%) |
I alter the dose of medicine. | 1 (1%) | 1 (1%) | 3 (3%) | 7 (5%) | 105 (90%) |
I stop taking the medicine for a while. | 1 (1%) | 2 (2%) | 4 (3%) | 9 (8%) | 101 (86%) |
I decided to miss out a dose. | 1 (1%) | 2 (2%) | 7 (5%) | 9 (8%) | 98 (84%) |
I take less than instructed. | 1 (1%) | 1 (1%) | 4 (3%) | 6 (5%) | 105 (90%) |
Questions | Always | Often | Occasionally | Rarely | Never |
---|---|---|---|---|---|
I forget to take the medicine. | 1 (1%) | 9 (5%) | 23 (14%) | 58 (36%) | 72 (44%) |
I alter the dose of medicine. | 0 (0%) | 3 (2%) | 6 (4%) | 19 (12%) | 135 (82%) |
I stop taking the medicine for a while. | 1 (1%) | 7 (4%) | 10 (6%) | 25 (15%) | 120 (74%) |
I decided to miss out a dose. | 0 (0%) | 3 (2%) | 11 (7%) | 27 (16%) | 122 (75%) |
I take less than instructed. | 1 (1%) | 2 (1%) | 6 (4%) | 17 (10%) | 137 (84%) |
Indices | MARS Questionnaire | CACHE Questionnaire | ||
---|---|---|---|---|
Adolescent Population | Adult Population | Adolescent Population | Adult Population | |
number of responses (n) | 117 | 163 | 122 | 164 |
total score, mean (SD) | 23 (2.907) | 23 (2.756) | 76 (12.369) | 72 (16.235) |
CFI | 0.987 | 0.971 | 0.937 | 0.971 |
TLI | 0.973 | 0.942 | 0.930 | 0.968 |
RMSEA (CI) | 0.174 (0.105–0.250) | 0.169 (0.112–0.232) | 0.071 (0.060–0.081) | 0.063 (0.055–0.72) |
Cronbach’s α | 0.864 | 0.790 | 0.906 | 0.945 |
number or retests (n) | 51 | 76 | 52 | 76 |
total score, mean (SD) | 24 (2.880) | 24 (2.154) | 70 (16.276) | 72 (17.551) |
test-retest: ρ (p) | 0.814 (0.001) | 0.780 (0.001) | 0.892 (0.001) | 0.898 (0.001) |
Questions | Totally Agree | Agree | Occasionally | Neither Agree nor Disagree | Disagree |
---|---|---|---|---|---|
My doctor spends an appropriate amount of time listening to and answering my questions about my bowel disease | 84 (69%) | 29 (24%) | 8 (6%) | 1 (1%) | 0 (0%) |
I have confidence in my doctor’s judgment when managing and treating my bowel disease | 93 (76%) | 18 (15%) | 10 (8%) | 1 (1%) | 0 (0%) |
understand the explanations given to me on my bowel disease, its treatment, and the side effects of treatment | 62 (51%) | 49 (40%) | 10 (8%) | 0 (0%) | 1 (1%) |
I get advice and guidance about nutrition, daily activities, exercise, etc, which I have to follow because of my bowel disease | 55 (45%) | 36 (30%) | 21 (17%) | 10 (8%) | 0 (0%) |
My doctor takes my opinion and preferences regarding treatment for my bowel disease into account | 64 (52%) | 44 (36%) | 11 (9%) | 2 (2%) | 1 (1%) |
The medical personnel who look after me know my medical history and concern themselves with the evolution of my bowel disease | 65 (53%) | 40 (33%) | 13 (11%) | 3 (2%) | 1 (1%) |
The center I go to have my condition treated is well-located and easily accessible | 52 (43%) | 40 (33%) | 18 (15%) | 9 (7%) | 3 (2%) |
The facilities at the hospital I go to treat my bowel disease are adequate and comfortable | 57 (46%) | 43 (35%) | 18 (15%) | 2 (2%) | 2 (2%) |
Communication with the medical staff treating me is appropriate and fluid | 57 (46%) | 43 (35%) | 18 (15%) | 2 (2%) | 2 (2%) |
I feel listened to and understood by the medical staff treating me when I explain my intestinal problems and the difficulties they cause me | 66 (54%) | 42 (34%) | 13 (11%) | 0 (0%) | 1 (1%) |
I worry about the price I have to pay for the drugs prescribed for my bowel disease | 9 (7%) | 15 (12%) | 22 (18%) | 36 (30%) | 40 (33%) |
For me, it is important that I always see the same medical team | 31 (26%) | 42 (34%) | 37 (30%) | 10 (8%) | 2 (2%) |
The staff take into account the consequences of my bowel disease treatment on my daily life | 61 (50%) | 48 (39%) | 12 (10%) | 1 (1%) | 0 (0%) |
I have been informed about how to contact with patients’ associations for people with intestinal problems like mine | 20 (16%) | 33 (27%) | 24 (20%) | 24 (20%) | 21 (17%) |
Having a specialist nurse in the medical team treating me would help me with my bowel disease | 28 (23%) | 35 (29%) | 38 (31%) | 12 (10%) | 9 (7%) |
The staff that look after me and the place I go for treatment motivate me to stick with the treatment for my illness | 62 (51%) | 41 (33%) | 12 (10%) | 5 (4%) | 2 (2%) |
The center where they administer my medication has the necessary resources and facilities | 73 (60%) | 37 (30%) | 9 (7%) | 2 (2%) | 1 (1%) |
At the hospital where I get treatment for my bowel disease, I can get information about my disease through brochures, information campaigns, etc | 24 (20%) | 36 (30%) | 37 (30%) | 14 (11%) | 11 (9%) |
I can see the clinician when I have a flare-up | 84 (69%) | 27 (22%) | 4 (3%) | 7 (6%) | 0 (0%) |
Being able to talk with people who have the same or similar problems as me while I am receiving my medication, helps me to share questions and concerns related to my bowel disease | 21 (17%) | 27 (22%) | 32 (27%) | 28 (23%) | 13 (11%) |
Visits can be scheduled on days and at times that least affect my daily activities (work, studies…) | 39 (32%) | 37 (30%) | 24 (20%) | 15 (12%) | 7 (6%) |
In the hospital, they treat me with sufficient intimacy and reserve | 76 (63%) | 36 (29%) | 5 (4%) | 3 (2%) | 2 (2%) |
The time I have to wait before being seen at the visit is reasonable | 43 (35%) | 46 (38%) | 23 (19%) | 7 (6%) | 3 (2%) |
In the center I go to for treatment, I can be attended over the phone | 68 (56%) | 34 (28%) | 17 (14%) | 3 (2%) | 0 (0%) |
The bathrooms in the center are adequate and accessible | 36 (30%) | 44 (36%) | 27 (22%) | 9 (7%) | 6 (5%) |
There is good coordination and communication between my medical team and other specialists and/or primary care | 46 (38%) | 38 (31%) | 23 (19%) | 12 (10%) | 3 (2%) |
I’m satisfied with the results of the treatment I receive | 58 (48%) | 38 (31%) | 22 (18%) | 4 (3%) | 0 (0%) |
If any problems arise with the treatment I am receiving, my medical team resolve it quickly and effectively | 63 (52%) | 47 (39%) | 8 (6%) | 4 (3%) | 0 (0%) |
I feel safer if I get the treatment at the hospital than if I had to do it at home | 38 (31%) | 25 (20%) | 32 (27%) | 17 (14%) | 10 (8%) |
I understand the instructions I’ve been given about my medication | 73 (60%) | 34 (27%) | 12 (10%) | 1 (1%) | 2 (2%) |
I’ve been given adequate information about the side effects of my medication | 61 (50%) | 38 (31%) | 17 (14%) | 4 (3%) | 2 (2%) |
Questions | Totally Agree | Agree | Occasionally | Neither Agree nor Disagree | Disagree |
---|---|---|---|---|---|
My doctor spends an appropriate amount of time listening to and answering my questions about my bowel disease | 89 (54%) | 36 (22%) | 31 (19%) | 7 (4%) | 1 (1%) |
I have confidence in my doctor’s judgment when managing and treating my bowel disease | 104 (63%) | 34 (21%) | 24 (15%) | 1 (1%) | 1 (1%) |
understand the explanations given to me on my bowel disease, its treatment, and the side effects of treatment | 79 (48%) | 63 (39%) | 20 (12%) | 2 (1%) | 0 (0%) |
I get advice and guidance about nutrition, daily activities, exercise, etc, which I have to follow because of my bowel disease | 58 (35%) | 41 (25%) | 44 (27%) | 13 (8%) | 8 (5%) |
My doctor takes my opinion and preferences regarding treatment for my bowel disease into account | 77 (47%) | 51 (31%) | 28 (17%) | 7 (4%) | 1 (1%) |
The medical personnel who look after me know my medical history and concern themselves with the evolution of my bowel disease | 75 (46%) | 42 (25%) | 28 (17%) | 13 (8%) | 6 (4%) |
The center I go to have my condition treated is well-located and easily accessible | 87 (53%) | 51 (31%) | 22 (14%) | 2 (1%) | 2 (1%) |
The facilities at the hospital I go to treat my bowel disease are adequate and comfortable | 76 (46%) | 53 (32%) | 26 (16%) | 6 (4%) | 3 (2%) |
Communication with the medical staff treating me is appropriate and fluid | 80 (49%) | 39 (24%) | 32 (19%) | 9 (6%) | 4 (2%) |
I feel listened to and understood by the medical staff treating me when I explain my intestinal problems and the difficulties they cause me | 74 (45%) | 60 (37%) | 20 (12%) | 8 (5%) | 2 (1%) |
I worry about the price I have to pay for the drugs prescribed for my bowel disease | 17 (11%) | 18 (11%) | 48 (29%) | 46 (28%) | 35 (21%) |
For me, it is important that I always see the same medical team | 70 (42%) | 64 (39%) | 23 (14%) | 6 (4%) | 1 (1%) |
The staff take into account the consequences of my bowel disease treatment on my daily life | 63 (39%) | 67 (40%) | 23 (14%) | 10 (6%) | 1 (1%) |
I have been informed about how to contact with patients’ associations for people with intestinal problems like mine | 32 (19%) | 46 (28%) | 25 (16%) | 29 (18%) | 32 (19%) |
Having a specialist nurse in the medical team treating me would help me with my bowel disease | 32 (19%) | 67 (40%) | 37 (24%) | 20 (12%) | 8 (5%) |
The staff that look after me and the place I go for treatment motivate me to stick with the treatment for my illness | 72 (44%) | 64 (39%) | 20 (12%) | 6 (4%) | 2 (1%) |
The center where they administer my medication has the necessary resources and facilities | 86 (52%) | 48 (29%) | 24 (15%) | 5 (3%) | 1 (1%) |
At the hospital where I get treatment for my bowel disease, I can get information about my disease through brochures, information campaigns, etc | 47 (28%) | 41 (25%) | 34 (21%) | 26 (16%) | 16 (10%) |
I can see the clinician when I have a flare-up | 73 (45%) | 53 (32%) | 24 (15%) | 10 (6%) | 4 (2%) |
Being able to talk with people who have the same or similar problems as me while I am receiving my medication, helps me to share questions and concerns related to my bowel disease | 31 (19%) | 40 (24%) | 40 (24%) | 32 (19%) | 21 (14%) |
Visits can be scheduled on days and at times that least affect my daily activities (work, studies…) | 53 (32%) | 42 (25%) | 30 (18%) | 25 (16%) | 14 (9%) |
In the hospital, they treat me with sufficient intimacy and reserve | 73 (45%) | 59 (36%) | 20 (12%) | 8 (5%) | 4 (2%) |
The time I have to wait before being seen at the visit is reasonable | 40 (25%) | 59 (36%) | 41 (25%) | 20 (12%) | 4 (2%) |
In the center I go to for treatment, I can be attended over the phone | 63 (39%) | 51 (31%) | 28 (17%) | 15 (9%) | 7 (4%) |
The bathrooms in the center are adequate and accessible | 42 (25%) | 51 (31%) | 42 (25%) | 13 (8%) | 16 (11%) |
There is good coordination and communication between my medical team and other specialists and/or primary care | 36 (22%) | 40 (24%) | 39 (24%) | 29 (18%) | 20 (12%) |
I’m satisfied with the results of the treatment I receive | 60 (37%) | 54 (33%) | 38 (23%) | 8 (5%) | 4 (2%) |
If any problems arise with the treatment I am receiving, my medical team resolve it quickly and effectively | 65 (40%) | 55 (33%) | 31 (19%) | 9 (6%) | 4 (2%) |
I feel safer if I get the treatment at the hospital than if I had to do it at home | 41 (25%) | 48 (29%) | 48 (29%) | 20 (12%) | 7 (5%) |
I understand the instructions I’ve been given about my medication | 99 (60%) | 56 (34%) | 8 (5%) | 1 (1%) | 0 (0%) |
I’ve been given adequate information about the side effects of my medication | 57 (35%) | 48 (29%) | 35 (21%) | 13 (8%) | 11 (7%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dohos, D.; Váradi, A.; Farkas, N.; Erős, A.; Párniczky, A.; Schäfer, E.; Kosaras, É.; Czelecz, J.; Hegyi, P.; Sarlós, P. Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS). Children 2022, 9, 1143. https://doi.org/10.3390/children9081143
Dohos D, Váradi A, Farkas N, Erős A, Párniczky A, Schäfer E, Kosaras É, Czelecz J, Hegyi P, Sarlós P. Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS). Children. 2022; 9(8):1143. https://doi.org/10.3390/children9081143
Chicago/Turabian StyleDohos, Dóra, Alex Váradi, Nelli Farkas, Adrienn Erős, Andrea Párniczky, Eszter Schäfer, Éva Kosaras, Judit Czelecz, Péter Hegyi, and Patrícia Sarlós. 2022. "Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS)" Children 9, no. 8: 1143. https://doi.org/10.3390/children9081143
APA StyleDohos, D., Váradi, A., Farkas, N., Erős, A., Párniczky, A., Schäfer, E., Kosaras, É., Czelecz, J., Hegyi, P., & Sarlós, P. (2022). Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS). Children, 9(8), 1143. https://doi.org/10.3390/children9081143